Last reviewed 2026-06-10 · How we verify

Congenital generalized lipodystrophy — Treatment Landscape & Competitive Intelligence

Congenital generalized lipodystrophy (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Congenital generalized lipodystrophy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Amylin Pharms Llc · 1 drug in Congenital generalized lipodystrophy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Congenital generalized lipodystrophy:

• Congenital generalized lipodystrophy treatment updates — RSS
• Congenital generalized lipodystrophy treatment updates — Atom
• Congenital generalized lipodystrophy treatment updates — JSON

Cite this brief

Drug Landscape (2026). Congenital generalized lipodystrophy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/congenital-generalized-lipodystrophy. Accessed 2026-06-10.

Related

• Congenital generalized lipodystrophy full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing